摘要
树突状细胞是体内最为强大的专职抗原递呈细胞，可激活机体初始免疫应答。已有的研究发现，侵入到肺癌组织的突状细胞存在成熟障碍，未成熟树的突状细胞不能有效地向肿瘤特异性T细胞递呈肿瘤抗原，同时通过诱导调节性T细胞的增殖参与肺癌的免疫逃逸。肺癌组织中的树突状细胞与患者临床预后密切相关，基于树突状细胞的肿瘤疫苗已作为肺癌生物治疗的手段之一得以深入研究并取得了令人满意的前期效果。
Dendritic cells are specialized antigen-presenting cells that have an unequaled capacity to initiate primary immune responses. The latest researches have shown that tumor infiltrating dendritic cells have dysmaturity, immature DC could not present tumor antigen to T lymphocyte efficiently, even participated in immune escape process of tumor cells through inducing proliferation of T regulatory cells. There exists a close correlation between tumor infiltrating dendritic cells and prognosis of cancer patients, DC-based vaccine have become one of methods of lung cancer immunotherapy and demonstrated satisfactory effect.
出处
《国际呼吸杂志》
2007年第6期454-456,共3页
International Journal of Respiration
基金
江苏省社会发展基金（编号：BS2000038）和江苏省医学重点人才基金（编号：RC2002032）
关键词
树突状细胞
肺癌
肿瘤浸润
预后
免疫治疗
Dendritic cell
Lung cancer
Tumor infiltrating
Prognosis
Immunotherapy
